Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. Our initial product candidate, vonoprazan, is a potassium competitive acid blocker (P-CAB), a new class of anti-secretory medicines with potential applications in GI diseases.
We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging.
We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.
We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging.
We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.
Location: United States, New Jersey, Florham Park
Employees: 51-200
Total raised: $140M
Founded date: 2018
Investors 7
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | Frazier Li... | frazierls.... |
| - | Abingworth... | abingworth... |
| - | Sahsen Ven... | sahsen.com |
| - | Catalys Pa... | catalyspac... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2019 | - | $140M | - |
Mentions in press and media 16
| Date | Title | Description |
| 19.08.2024 | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants | FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pr... |
| 07.03.2024 | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 01.11.2022 | Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement | - |
| 04.05.2022 | Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital | Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase... |
| 03.05.2022 | Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infec... | FLORHAM PARK, N.J., May 03, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S.... |
| 18.10.2021 | Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial | FLORHAM PARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, tod... |
| 20.09.2021 | Phathom Pharmaceuticals, Inc. Secures $200 Million Term Loan Facility from Hercules Capital | Phathom Pharmaceuticals, Inc. reported it has obtained a $200 million term loan facility from Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capit... |
| 20.09.2021 | Hercules Capital : Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital | FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, t... |
| 16.09.2021 | Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals | As Phathom readies for the potential approval and launch of our first product, we are pleased to have secured Catalent as a strategic partner to support our vonoprazan commercial manufacturing and packaging capabilities. SOMERSET, N.J. (PRW... |
| 08.09.2021 | Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection | With current standard of care therapies, H. pylori eradication rates have declined in the U.S. If approved, vonoprazan-based treatments offer two new therapeutic options that have demonstrated superior eradication rates as compared to stand... |
Show more